ログイン

MUST KNOWS 1

MUST KNOWS 1
100問 • 1年前
  • Yves Laure Pimentel
  • 通報

    問題一覧

  • 1

    NK cells + IL-2

    LAK cells

  • 2

    Against cancer

    LAK cells

  • 3

    capacity of killing NK-resistant fresh human tumor cells in short-term assays

    LAK cells

  • 4

    (-) Markers on T/B cells

    NK/Null/3rd population lymphocyte

  • 5

    Kills virus and tumor cells

    NK/Null/3rd population lymphocyte

  • 6

    CD 16, CD 56

    NK/Null/3rd population lymphocyte

  • 7

    Major humoral immunity (natural)

    Complement

  • 8

    “ICED”: Initiation, Chemotaxis, Engulfment, Digestion

    Phagocytosis

  • 9

    Phagocytosis

    “ICED”: Initiation, Chemotaxis, Engulfment, Digestion

  • 10

    Primitive pattern recognition receptor

    Direct phagocytosis

  • 11

    Via opsonins

    Indirect phagocytosis

  • 12

    CR3 (3rd C’ component)

    Initiation

  • 13

    Laminin receptor

    Initiation

  • 14

    Leucyl-formyl-methionyl-phenylalanine receptor

    Initiation

  • 15

    (potent chemotaxin)

    C5a

  • 16

    C5a (potent chemotaxin)

    Chemotaxis

  • 17

    = test for chemotaxis

    Boyden Chamber assay

  • 18

    C3b (opsonin)

    Engulfment

  • 19

    From eosinophils and mast cells

    Histamine

  • 20

    Vasodilation

    Histamine

  • 21

    Lymphokine activating factor

    IL-1

  • 22

    Secreted by monocytes and macrophages

    IL-1

  • 23

    Mediates fever

    IL-1

  • 24

    INCREASED APR’s

    IL-1

  • 25

    Stabilize the wound area

    Fibroblasts

  • 26

    has been recognized as the prototype acute phase reactant

    CRP

  • 27

    INCREASED 20-1,000x

    CRP Serum amyloid A

  • 28

    Young cells

    Fibroblasts

  • 29

    Leukocyte IFN (Type 1

    IFN-a

  • 30

    Produced by viral-induced leukocyte culture

    IFN-a

  • 31

    Major producer: NK cell

    IFN-a

  • 32

    IFN-a Major producer:

    NK cell

  • 33

    WHAT TYPE? IFN-α

    Leukocyte IFN (Type 1)

  • 34

    WHAT TYPE? IFN-β

    Fibroepithelial IFN (Type 1)

  • 35

    Fibroepithelial IFN (Type 1)

    IFN-β

  • 36

    Produced by dsRNA fibroblast cells

    IFN-ß

  • 37

    WHAT TYPE? IFN-γ

    Immune interferon (Type 2)

  • 38

    Produced by immunologically-stimulated lymphocytes

    IFN-γ

  • 39

    is a cytokine that is critical for innate and adaptive immunity against viral, some bacterial and protozoan infections

    IFN-γ

  • 40

    TNF-α AKA

    Cachectin

  • 41

    Produced by macrophages

    TNF-α AKA Cachectin

  • 42

    TNF-β AKA

    Lymphotoxin

  • 43

    Produced by CD4+ and CD8+ lymphocytes

    TNF-β AKA Lymphotoxin

  • 44

    TNF-β AKA Lymphotoxin Produced by ?

    CD4+ and CD8+ lymphocytes

  • 45

    (3) Large capsule Cause meningitis

    H. influenzae N. meningitidis S. pneumoniae

  • 46

    (-) NADPH oxidase

    CGD

  • 47

    Test for CGD

    NBT dye test

  • 48

    Regulates body temperature (fever)

    Hypothalamus

  • 49

    increased γ-globulins (increased plasma cells)

    Chronic inflammation

  • 50

    Antigen in unrelated plants and animals but are closely linked that they cross react with one another

    Heterophile antigens

  • 51

    Order of activation (C’)

    C142356789

  • 52

    Serum protein Bactericidal and viricidal Needs C3 and Mg2+

    Properdin

  • 53

    Bactericidal and viricidal

    Properdin

  • 54

    Needs C3 and Mg2+

    Properdin

  • 55

    Released by platelets

    Betalysin

  • 56

    is an amino acid produced by platelets during coagulation and is directly antibacterial by causing lysis of many Gram positive bacteria by acting as a cationic detergent

    β-Lysine

  • 57

    Against Gram (+) except Streptococcus

    β-Lysine

  • 58

    β-Lysine Against Gram (+) except ?

    Streptococcus

  • 59

    Antibody production is done by the body

    Active immunity

  • 60

    Active immunity Advantage:

    Long term

  • 61

    Active immunity Disadvantage:

    slow response

  • 62

    Infection (Ag)

    Active natural

  • 63

    Vaccination (Ag)

    Active artificial

  • 64

    Vaccines: 1. Live =

    smallpox

  • 65

    Vaccines: 1. = smallpox

    Live

  • 66

    Vaccines: Attenuated =

    BCG-Bacillus Calmette Guérin (M. bovis)

  • 67

    Vaccines: Dead =

    cholera, typhoid

  • 68

    Vaccines: = cholera, typhoid

    Dead

  • 69

    Vaccines: = BCG (M. bovis)

    Attenuated

  • 70

    Vaccines: Toxoid =

    C. tetani

  • 71

    Vaccines: = C. tetani

    Toxoid

  • 72

    Vaccines: Modified virus =

    poliovirus

  • 73

    Vaccines: = poliovirus

    Modified virus

  • 74

    Antibody production is not done by the body

    Passive immunity

  • 75

    Passive immunity Advantage:

    Immediate

  • 76

    Passive immunity Disadvantage:

    short term

  • 77

    Transfer in vivo (Ab)

    Passive natural

  • 78

    Immune serum Ig’s administration (Ab) Ex. anti-rabies

    Passive artificial

  • 79

    German word: Swelling

    Quellung

  • 80

    Quellung also called the

    Neufeld reaction

  • 81

    gold standard method for pneumococcal capsular serotyping

    Quellung test

  • 82

    Highest eosinophil count

    T. spiralis

  • 83

    Maturation of T and B cells

    1’/ PRIMARY lymphoid organs

  • 84

    Proliferation and differentiation of T and B cells

    2’/ Secondary lymphoid organs

  • 85

    2’/ Secondary lymphoid organs

    Spleen Peyer’s patches Lymph nodes

  • 86

    generally regarded as a B-dependent area

    lymph node cortex

  • 87

    Lymph nodes Cortex =

    B cells

  • 88

    Lymph nodes Paracortex =

    T cells

  • 89

    T cells are found mainly in the

    Paracortex

  • 90

    % of total lymphocytes

    80%

  • 91

    Sheep RBC receptor, classical T-cell surface marker

    CD2

  • 92

    CD? (4) T lymphocytes

    CD2 CD3 CD4 CD8

  • 93

    part of T cell Ag-receptor complex

    CD3

  • 94

    MHC class II (Th)

    CD4

  • 95

    = MHC class I (Tc/Ts)

    CD8

  • 96

    the development in an individual of the immune system from fetal life though adulthood

    Ontogeny

  • 97

    Ontogeny of T cells (Thymus) Cortex =

    Immature (85% )

  • 98

    Ontogeny of T cells (Thymus) PART? = Immature (85% )

    Cortex

  • 99

    Ontogeny of T cells (Thymus) PART? = Mature (15%)

    Medulla

  • 100

    Ontogeny of T cells (Thymus) Medulla =

    Mature (15%)

  • other names parasitology

    other names parasitology

    Yves Laure Pimentel · 70問 · 2年前

    other names parasitology

    other names parasitology

    70問 • 2年前
    Yves Laure Pimentel

    PARASITOLOGY

    PARASITOLOGY

    Yves Laure Pimentel · 111問 · 2年前

    PARASITOLOGY

    PARASITOLOGY

    111問 • 2年前
    Yves Laure Pimentel

    HTMLBE

    HTMLBE

    Yves Laure Pimentel · 64問 · 2年前

    HTMLBE

    HTMLBE

    64問 • 2年前
    Yves Laure Pimentel

    CC - 1 LAB. SAFETY, BASIC UNITS, AND CONVERSION FACTOR

    CC - 1 LAB. SAFETY, BASIC UNITS, AND CONVERSION FACTOR

    Yves Laure Pimentel · 61問 · 2年前

    CC - 1 LAB. SAFETY, BASIC UNITS, AND CONVERSION FACTOR

    CC - 1 LAB. SAFETY, BASIC UNITS, AND CONVERSION FACTOR

    61問 • 2年前
    Yves Laure Pimentel

    HISTOPATHOLOGY

    HISTOPATHOLOGY

    Yves Laure Pimentel · 69問 · 2年前

    HISTOPATHOLOGY

    HISTOPATHOLOGY

    69問 • 2年前
    Yves Laure Pimentel

    CC-2 SPECTROPHOTOMETRY

    CC-2 SPECTROPHOTOMETRY

    Yves Laure Pimentel · 100問 · 2年前

    CC-2 SPECTROPHOTOMETRY

    CC-2 SPECTROPHOTOMETRY

    100問 • 2年前
    Yves Laure Pimentel

    CC-3 ELECTROPHORESIS

    CC-3 ELECTROPHORESIS

    Yves Laure Pimentel · 41問 · 2年前

    CC-3 ELECTROPHORESIS

    CC-3 ELECTROPHORESIS

    41問 • 2年前
    Yves Laure Pimentel

    AUBF LAB SAFETY

    AUBF LAB SAFETY

    Yves Laure Pimentel · 87問 · 2年前

    AUBF LAB SAFETY

    AUBF LAB SAFETY

    87問 • 2年前
    Yves Laure Pimentel

    CSF 1

    CSF 1

    Yves Laure Pimentel · 100問 · 2年前

    CSF 1

    CSF 1

    100問 • 2年前
    Yves Laure Pimentel

    CSF 2

    CSF 2

    Yves Laure Pimentel · 82問 · 2年前

    CSF 2

    CSF 2

    82問 • 2年前
    Yves Laure Pimentel

    SEMEN 1

    SEMEN 1

    Yves Laure Pimentel · 100問 · 2年前

    SEMEN 1

    SEMEN 1

    100問 • 2年前
    Yves Laure Pimentel

    SEMEN 2

    SEMEN 2

    Yves Laure Pimentel · 7問 · 2年前

    SEMEN 2

    SEMEN 2

    7問 • 2年前
    Yves Laure Pimentel

    SYNOVIAL FLUID 1

    SYNOVIAL FLUID 1

    Yves Laure Pimentel · 100問 · 2年前

    SYNOVIAL FLUID 1

    SYNOVIAL FLUID 1

    100問 • 2年前
    Yves Laure Pimentel

    SYNOVIAL FLUID 2

    SYNOVIAL FLUID 2

    Yves Laure Pimentel · 6問 · 2年前

    SYNOVIAL FLUID 2

    SYNOVIAL FLUID 2

    6問 • 2年前
    Yves Laure Pimentel

    SEROUS FLUID

    SEROUS FLUID

    Yves Laure Pimentel · 25問 · 2年前

    SEROUS FLUID

    SEROUS FLUID

    25問 • 2年前
    Yves Laure Pimentel

    PLEURAL FLUID

    PLEURAL FLUID

    Yves Laure Pimentel · 44問 · 2年前

    PLEURAL FLUID

    PLEURAL FLUID

    44問 • 2年前
    Yves Laure Pimentel

    PERICARDIAL FLUID

    PERICARDIAL FLUID

    Yves Laure Pimentel · 18問 · 2年前

    PERICARDIAL FLUID

    PERICARDIAL FLUID

    18問 • 2年前
    Yves Laure Pimentel

    PERITONEAL FLUID/ ASCITIC FLUID

    PERITONEAL FLUID/ ASCITIC FLUID

    Yves Laure Pimentel · 30問 · 2年前

    PERITONEAL FLUID/ ASCITIC FLUID

    PERITONEAL FLUID/ ASCITIC FLUID

    30問 • 2年前
    Yves Laure Pimentel

    AMNIOTIC FLUID

    AMNIOTIC FLUID

    Yves Laure Pimentel · 92問 · 2年前

    AMNIOTIC FLUID

    AMNIOTIC FLUID

    92問 • 2年前
    Yves Laure Pimentel

    FECALYSIS

    FECALYSIS

    Yves Laure Pimentel · 80問 · 2年前

    FECALYSIS

    FECALYSIS

    80問 • 2年前
    Yves Laure Pimentel

    OTHER BODY FLUIDS

    OTHER BODY FLUIDS

    Yves Laure Pimentel · 89問 · 2年前

    OTHER BODY FLUIDS

    OTHER BODY FLUIDS

    89問 • 2年前
    Yves Laure Pimentel

    MTLBE- SUHO NOTES

    MTLBE- SUHO NOTES

    Yves Laure Pimentel · 86問 · 2年前

    MTLBE- SUHO NOTES

    MTLBE- SUHO NOTES

    86問 • 2年前
    Yves Laure Pimentel

    MTLBE..

    MTLBE..

    Yves Laure Pimentel · 35問 · 2年前

    MTLBE..

    MTLBE..

    35問 • 2年前
    Yves Laure Pimentel

    CC- CHROMATOGRAPHY

    CC- CHROMATOGRAPHY

    Yves Laure Pimentel · 19問 · 1年前

    CC- CHROMATOGRAPHY

    CC- CHROMATOGRAPHY

    19問 • 1年前
    Yves Laure Pimentel

    CC-OSMOMETRY

    CC-OSMOMETRY

    Yves Laure Pimentel · 14問 · 1年前

    CC-OSMOMETRY

    CC-OSMOMETRY

    14問 • 1年前
    Yves Laure Pimentel

    CC-ELECTROCHEMISTRY TECHNIQUES

    CC-ELECTROCHEMISTRY TECHNIQUES

    Yves Laure Pimentel · 43問 · 1年前

    CC-ELECTROCHEMISTRY TECHNIQUES

    CC-ELECTROCHEMISTRY TECHNIQUES

    43問 • 1年前
    Yves Laure Pimentel

    CC- CARBOHYDRATES

    CC- CARBOHYDRATES

    Yves Laure Pimentel · 49問 · 2年前

    CC- CARBOHYDRATES

    CC- CARBOHYDRATES

    49問 • 2年前
    Yves Laure Pimentel

    CC- DIABETES MELLITUS

    CC- DIABETES MELLITUS

    Yves Laure Pimentel · 97問 · 2年前

    CC- DIABETES MELLITUS

    CC- DIABETES MELLITUS

    97問 • 2年前
    Yves Laure Pimentel

    MAJOR LIPOPROTEINS

    MAJOR LIPOPROTEINS

    Yves Laure Pimentel · 57問 · 2年前

    MAJOR LIPOPROTEINS

    MAJOR LIPOPROTEINS

    57問 • 2年前
    Yves Laure Pimentel

    MINOR LIPOPROTEINS

    MINOR LIPOPROTEINS

    Yves Laure Pimentel · 63問 · 2年前

    MINOR LIPOPROTEINS

    MINOR LIPOPROTEINS

    63問 • 2年前
    Yves Laure Pimentel

    PROTEINS

    PROTEINS

    Yves Laure Pimentel · 37問 · 2年前

    PROTEINS

    PROTEINS

    37問 • 2年前
    Yves Laure Pimentel

    PLASMA PROTEINS 1

    PLASMA PROTEINS 1

    Yves Laure Pimentel · 91問 · 2年前

    PLASMA PROTEINS 1

    PLASMA PROTEINS 1

    91問 • 2年前
    Yves Laure Pimentel

    PLASMA PROTEINS 2 (ALPHA 2 REGION)

    PLASMA PROTEINS 2 (ALPHA 2 REGION)

    Yves Laure Pimentel · 98問 · 2年前

    PLASMA PROTEINS 2 (ALPHA 2 REGION)

    PLASMA PROTEINS 2 (ALPHA 2 REGION)

    98問 • 2年前
    Yves Laure Pimentel

    MISCELLANEOUS PROTEINS

    MISCELLANEOUS PROTEINS

    Yves Laure Pimentel · 61問 · 2年前

    MISCELLANEOUS PROTEINS

    MISCELLANEOUS PROTEINS

    61問 • 2年前
    Yves Laure Pimentel

    Liver Function Test 1

    Liver Function Test 1

    Yves Laure Pimentel · 100問 · 2年前

    Liver Function Test 1

    Liver Function Test 1

    100問 • 2年前
    Yves Laure Pimentel

    Liver Function Test 2

    Liver Function Test 2

    Yves Laure Pimentel · 96問 · 2年前

    Liver Function Test 2

    Liver Function Test 2

    96問 • 2年前
    Yves Laure Pimentel

    TUMOR MARKERS

    TUMOR MARKERS

    Yves Laure Pimentel · 33問 · 2年前

    TUMOR MARKERS

    TUMOR MARKERS

    33問 • 2年前
    Yves Laure Pimentel

    KIDNEY FUNCTION TESTS - NON PROTEIN NITROGEN & CREATININE

    KIDNEY FUNCTION TESTS - NON PROTEIN NITROGEN & CREATININE

    Yves Laure Pimentel · 41問 · 2年前

    KIDNEY FUNCTION TESTS - NON PROTEIN NITROGEN & CREATININE

    KIDNEY FUNCTION TESTS - NON PROTEIN NITROGEN & CREATININE

    41問 • 2年前
    Yves Laure Pimentel

    GLYCOGEN STORAGE DISEASES

    GLYCOGEN STORAGE DISEASES

    Yves Laure Pimentel · 17問 · 2年前

    GLYCOGEN STORAGE DISEASES

    GLYCOGEN STORAGE DISEASES

    17問 • 2年前
    Yves Laure Pimentel

    LIPID STORAGE DISEASES

    LIPID STORAGE DISEASES

    Yves Laure Pimentel · 14問 · 2年前

    LIPID STORAGE DISEASES

    LIPID STORAGE DISEASES

    14問 • 2年前
    Yves Laure Pimentel

    PROTEINS

    PROTEINS

    Yves Laure Pimentel · 71問 · 2年前

    PROTEINS

    PROTEINS

    71問 • 2年前
    Yves Laure Pimentel

    QUICK FIRE- ELECTRODES

    QUICK FIRE- ELECTRODES

    Yves Laure Pimentel · 7問 · 2年前

    QUICK FIRE- ELECTRODES

    QUICK FIRE- ELECTRODES

    7問 • 2年前
    Yves Laure Pimentel

    ELECTROLYTES

    ELECTROLYTES

    Yves Laure Pimentel · 10問 · 2年前

    ELECTROLYTES

    ELECTROLYTES

    10問 • 2年前
    Yves Laure Pimentel

    DRUGS

    DRUGS

    Yves Laure Pimentel · 27問 · 2年前

    DRUGS

    DRUGS

    27問 • 2年前
    Yves Laure Pimentel

    TOXIC AGENTS:

    TOXIC AGENTS:

    Yves Laure Pimentel · 12問 · 2年前

    TOXIC AGENTS:

    TOXIC AGENTS:

    12問 • 2年前
    Yves Laure Pimentel

    HEMATOLOGY 1 (HEMATOPOIESIS 1)

    HEMATOLOGY 1 (HEMATOPOIESIS 1)

    Yves Laure Pimentel · 100問 · 2年前

    HEMATOLOGY 1 (HEMATOPOIESIS 1)

    HEMATOLOGY 1 (HEMATOPOIESIS 1)

    100問 • 2年前
    Yves Laure Pimentel

    HEMATOLOGY (HEMATOPOIESIS 2)

    HEMATOLOGY (HEMATOPOIESIS 2)

    Yves Laure Pimentel · 29問 · 2年前

    HEMATOLOGY (HEMATOPOIESIS 2)

    HEMATOLOGY (HEMATOPOIESIS 2)

    29問 • 2年前
    Yves Laure Pimentel

    hema diseases

    hema diseases

    Yves Laure Pimentel · 25問 · 2年前

    hema diseases

    hema diseases

    25問 • 2年前
    Yves Laure Pimentel

    AML

    AML

    Yves Laure Pimentel · 43問 · 2年前

    AML

    AML

    43問 • 2年前
    Yves Laure Pimentel

    GLOBIN SYNTHESIS

    GLOBIN SYNTHESIS

    Yves Laure Pimentel · 71問 · 2年前

    GLOBIN SYNTHESIS

    GLOBIN SYNTHESIS

    71問 • 2年前
    Yves Laure Pimentel

    HEMATOLOGY REFERENCE RANGES

    HEMATOLOGY REFERENCE RANGES

    Yves Laure Pimentel · 31問 · 2年前

    HEMATOLOGY REFERENCE RANGES

    HEMATOLOGY REFERENCE RANGES

    31問 • 2年前
    Yves Laure Pimentel

    DISORDERS OF PRIMARY HEMOSTASIS

    DISORDERS OF PRIMARY HEMOSTASIS

    Yves Laure Pimentel · 34問 · 2年前

    DISORDERS OF PRIMARY HEMOSTASIS

    DISORDERS OF PRIMARY HEMOSTASIS

    34問 • 2年前
    Yves Laure Pimentel

    PLATELET DISORDERS

    PLATELET DISORDERS

    Yves Laure Pimentel · 37問 · 2年前

    PLATELET DISORDERS

    PLATELET DISORDERS

    37問 • 2年前
    Yves Laure Pimentel

    CHARACTERISTICS OF CLOTTING FACTORS

    CHARACTERISTICS OF CLOTTING FACTORS

    Yves Laure Pimentel · 100問 · 2年前

    CHARACTERISTICS OF CLOTTING FACTORS

    CHARACTERISTICS OF CLOTTING FACTORS

    100問 • 2年前
    Yves Laure Pimentel

    4. CLASSIFICATION OF MACROPHAGE

    4. CLASSIFICATION OF MACROPHAGE

    Yves Laure Pimentel · 12問 · 2年前

    4. CLASSIFICATION OF MACROPHAGE

    4. CLASSIFICATION OF MACROPHAGE

    12問 • 2年前
    Yves Laure Pimentel

    3. NATURAL OR INNATE IMMUNITY

    3. NATURAL OR INNATE IMMUNITY

    Yves Laure Pimentel · 39問 · 2年前

    3. NATURAL OR INNATE IMMUNITY

    3. NATURAL OR INNATE IMMUNITY

    39問 • 2年前
    Yves Laure Pimentel

    5. INTERNAL DEFENSE:SOLUBLE FACTORS (ACUTE PHASE REACTANTS)

    5. INTERNAL DEFENSE:SOLUBLE FACTORS (ACUTE PHASE REACTANTS)

    Yves Laure Pimentel · 55問 · 2年前

    5. INTERNAL DEFENSE:SOLUBLE FACTORS (ACUTE PHASE REACTANTS)

    5. INTERNAL DEFENSE:SOLUBLE FACTORS (ACUTE PHASE REACTANTS)

    55問 • 2年前
    Yves Laure Pimentel

    6. PHAGOCYTOSIS Chemotaxis

    6. PHAGOCYTOSIS Chemotaxis

    Yves Laure Pimentel · 37問 · 2年前

    6. PHAGOCYTOSIS Chemotaxis

    6. PHAGOCYTOSIS Chemotaxis

    37問 • 2年前
    Yves Laure Pimentel

    8. NATURE OF ANTIGEN

    8. NATURE OF ANTIGEN

    Yves Laure Pimentel · 44問 · 2年前

    8. NATURE OF ANTIGEN

    8. NATURE OF ANTIGEN

    44問 • 2年前
    Yves Laure Pimentel

    9. MAJOR HISTOCOMPATIBILITY COMPLEX/HUMAN LEUKOCYTE ANTIGEN

    9. MAJOR HISTOCOMPATIBILITY COMPLEX/HUMAN LEUKOCYTE ANTIGEN

    Yves Laure Pimentel · 50問 · 2年前

    9. MAJOR HISTOCOMPATIBILITY COMPLEX/HUMAN LEUKOCYTE ANTIGEN

    9. MAJOR HISTOCOMPATIBILITY COMPLEX/HUMAN LEUKOCYTE ANTIGEN

    50問 • 2年前
    Yves Laure Pimentel

    1. HISTORY

    1. HISTORY

    Yves Laure Pimentel · 69問 · 2年前

    1. HISTORY

    1. HISTORY

    69問 • 2年前
    Yves Laure Pimentel

    2. TYPES OF IMMUNITY

    2. TYPES OF IMMUNITY

    Yves Laure Pimentel · 38問 · 2年前

    2. TYPES OF IMMUNITY

    2. TYPES OF IMMUNITY

    38問 • 2年前
    Yves Laure Pimentel

    7. PHAGOCYTOSIS Engulfment and Digestion

    7. PHAGOCYTOSIS Engulfment and Digestion

    Yves Laure Pimentel · 21問 · 2年前

    7. PHAGOCYTOSIS Engulfment and Digestion

    7. PHAGOCYTOSIS Engulfment and Digestion

    21問 • 2年前
    Yves Laure Pimentel

    8. PHAGOCYTOSIS EXOCYTOSIS

    8. PHAGOCYTOSIS EXOCYTOSIS

    Yves Laure Pimentel · 15問 · 2年前

    8. PHAGOCYTOSIS EXOCYTOSIS

    8. PHAGOCYTOSIS EXOCYTOSIS

    15問 • 2年前
    Yves Laure Pimentel

    10. DISEASE ASSOCIATED TO HUMAN LEUKOCYTE ANTIGEN (henry)

    10. DISEASE ASSOCIATED TO HUMAN LEUKOCYTE ANTIGEN (henry)

    Yves Laure Pimentel · 32問 · 2年前

    10. DISEASE ASSOCIATED TO HUMAN LEUKOCYTE ANTIGEN (henry)

    10. DISEASE ASSOCIATED TO HUMAN LEUKOCYTE ANTIGEN (henry)

    32問 • 2年前
    Yves Laure Pimentel

    11. TRANSPLANTATION IMMUNOLOGY

    11. TRANSPLANTATION IMMUNOLOGY

    Yves Laure Pimentel · 30問 · 2年前

    11. TRANSPLANTATION IMMUNOLOGY

    11. TRANSPLANTATION IMMUNOLOGY

    30問 • 2年前
    Yves Laure Pimentel

    2. LYMPHOID ORGANS

    2. LYMPHOID ORGANS

    Yves Laure Pimentel · 38問 · 2年前

    2. LYMPHOID ORGANS

    2. LYMPHOID ORGANS

    38問 • 2年前
    Yves Laure Pimentel

    3. CLUSTER OF DIFFERENTIATION

    3. CLUSTER OF DIFFERENTIATION

    Yves Laure Pimentel · 48問 · 2年前

    3. CLUSTER OF DIFFERENTIATION

    3. CLUSTER OF DIFFERENTIATION

    48問 • 2年前
    Yves Laure Pimentel

    4. T-CELL DIFFERENTIATION

    4. T-CELL DIFFERENTIATION

    Yves Laure Pimentel · 35問 · 2年前

    4. T-CELL DIFFERENTIATION

    4. T-CELL DIFFERENTIATION

    35問 • 2年前
    Yves Laure Pimentel

    5. T CELL IMMUNODEFICIENCIES

    5. T CELL IMMUNODEFICIENCIES

    Yves Laure Pimentel · 18問 · 2年前

    5. T CELL IMMUNODEFICIENCIES

    5. T CELL IMMUNODEFICIENCIES

    18問 • 2年前
    Yves Laure Pimentel

    6. STAGES IN B-CELL DIFFERENTIATION  PROPIMAP

    6. STAGES IN B-CELL DIFFERENTIATION  PROPIMAP

    Yves Laure Pimentel · 44問 · 2年前

    6. STAGES IN B-CELL DIFFERENTIATION  PROPIMAP

    6. STAGES IN B-CELL DIFFERENTIATION  PROPIMAP

    44問 • 2年前
    Yves Laure Pimentel

    7. B CELL IMMUNODEFICIENCIES

    7. B CELL IMMUNODEFICIENCIES

    Yves Laure Pimentel · 23問 · 2年前

    7. B CELL IMMUNODEFICIENCIES

    7. B CELL IMMUNODEFICIENCIES

    23問 • 2年前
    Yves Laure Pimentel

    8. COMBINED T CELL AND B CELL DEFICIENCIES

    8. COMBINED T CELL AND B CELL DEFICIENCIES

    Yves Laure Pimentel · 34問 · 2年前

    8. COMBINED T CELL AND B CELL DEFICIENCIES

    8. COMBINED T CELL AND B CELL DEFICIENCIES

    34問 • 2年前
    Yves Laure Pimentel

    9. COMPARISON OF T AND B CELLS

    9. COMPARISON OF T AND B CELLS

    Yves Laure Pimentel · 12問 · 2年前

    9. COMPARISON OF T AND B CELLS

    9. COMPARISON OF T AND B CELLS

    12問 • 2年前
    Yves Laure Pimentel

    10. LABORATORY IDENTIFICATION OF LYMPHOCYTES

    10. LABORATORY IDENTIFICATION OF LYMPHOCYTES

    Yves Laure Pimentel · 16問 · 2年前

    10. LABORATORY IDENTIFICATION OF LYMPHOCYTES

    10. LABORATORY IDENTIFICATION OF LYMPHOCYTES

    16問 • 2年前
    Yves Laure Pimentel

    11. NATURAL KILLER CELLS OR THIRD POPULATION CELL

    11. NATURAL KILLER CELLS OR THIRD POPULATION CELL

    Yves Laure Pimentel · 15問 · 2年前

    11. NATURAL KILLER CELLS OR THIRD POPULATION CELL

    11. NATURAL KILLER CELLS OR THIRD POPULATION CELL

    15問 • 2年前
    Yves Laure Pimentel

    12. ANTIBODY

    12. ANTIBODY

    Yves Laure Pimentel · 79問 · 2年前

    12. ANTIBODY

    12. ANTIBODY

    79問 • 2年前
    Yves Laure Pimentel

    13. TYPES OF ANTIBODIES

    13. TYPES OF ANTIBODIES

    Yves Laure Pimentel · 97問 · 2年前

    13. TYPES OF ANTIBODIES

    13. TYPES OF ANTIBODIES

    97問 • 2年前
    Yves Laure Pimentel

    14. MONOCLONAL ANTIBODIES

    14. MONOCLONAL ANTIBODIES

    Yves Laure Pimentel · 11問 · 2年前

    14. MONOCLONAL ANTIBODIES

    14. MONOCLONAL ANTIBODIES

    11問 • 2年前
    Yves Laure Pimentel

    1. INTERLEUKINS

    1. INTERLEUKINS

    Yves Laure Pimentel · 23問 · 2年前

    1. INTERLEUKINS

    1. INTERLEUKINS

    23問 • 2年前
    Yves Laure Pimentel

    2. INTERFERONS

    2. INTERFERONS

    Yves Laure Pimentel · 28問 · 2年前

    2. INTERFERONS

    2. INTERFERONS

    28問 • 2年前
    Yves Laure Pimentel

    3. CYTOKINES IN THE INNATE AND ADAPTIVE IMMUNITY

    3. CYTOKINES IN THE INNATE AND ADAPTIVE IMMUNITY

    Yves Laure Pimentel · 8問 · 2年前

    3. CYTOKINES IN THE INNATE AND ADAPTIVE IMMUNITY

    3. CYTOKINES IN THE INNATE AND ADAPTIVE IMMUNITY

    8問 • 2年前
    Yves Laure Pimentel

    4. COMPLEMENT SYSTEM

    4. COMPLEMENT SYSTEM

    Yves Laure Pimentel · 19問 · 2年前

    4. COMPLEMENT SYSTEM

    4. COMPLEMENT SYSTEM

    19問 • 2年前
    Yves Laure Pimentel

    15. COMPLEMENT SYSTEM

    15. COMPLEMENT SYSTEM

    Yves Laure Pimentel · 76問 · 2年前

    15. COMPLEMENT SYSTEM

    15. COMPLEMENT SYSTEM

    76問 • 2年前
    Yves Laure Pimentel

    16. SYSTEM CONTROLS/COMPLEMENT REGULATION

    16. SYSTEM CONTROLS/COMPLEMENT REGULATION

    Yves Laure Pimentel · 21問 · 2年前

    16. SYSTEM CONTROLS/COMPLEMENT REGULATION

    16. SYSTEM CONTROLS/COMPLEMENT REGULATION

    21問 • 2年前
    Yves Laure Pimentel

    17. COMPLEMENT AND DISEASE STATES

    17. COMPLEMENT AND DISEASE STATES

    Yves Laure Pimentel · 29問 · 2年前

    17. COMPLEMENT AND DISEASE STATES

    17. COMPLEMENT AND DISEASE STATES

    29問 • 2年前
    Yves Laure Pimentel

    18. IMMUNOLOGIC ASSAYS OF INDIVIDUAL COMPONENTS (CLASSICAL)

    18. IMMUNOLOGIC ASSAYS OF INDIVIDUAL COMPONENTS (CLASSICAL)

    Yves Laure Pimentel · 19問 · 2年前

    18. IMMUNOLOGIC ASSAYS OF INDIVIDUAL COMPONENTS (CLASSICAL)

    18. IMMUNOLOGIC ASSAYS OF INDIVIDUAL COMPONENTS (CLASSICAL)

    19問 • 2年前
    Yves Laure Pimentel

    19. CYTOKINES

    19. CYTOKINES

    Yves Laure Pimentel · 22問 · 2年前

    19. CYTOKINES

    19. CYTOKINES

    22問 • 2年前
    Yves Laure Pimentel

    20. INTERLEUKINS

    20. INTERLEUKINS

    Yves Laure Pimentel · 24問 · 2年前

    20. INTERLEUKINS

    20. INTERLEUKINS

    24問 • 2年前
    Yves Laure Pimentel

    21. INTERFERONS, TNF, TGF, CHEMOKINE

    21. INTERFERONS, TNF, TGF, CHEMOKINE

    Yves Laure Pimentel · 21問 · 2年前

    21. INTERFERONS, TNF, TGF, CHEMOKINE

    21. INTERFERONS, TNF, TGF, CHEMOKINE

    21問 • 2年前
    Yves Laure Pimentel

    1. SERO

    1. SERO

    Yves Laure Pimentel · 54問 · 2年前

    1. SERO

    1. SERO

    54問 • 2年前
    Yves Laure Pimentel

    2. PRECIPITATION

    2. PRECIPITATION

    Yves Laure Pimentel · 38問 · 2年前

    2. PRECIPITATION

    2. PRECIPITATION

    38問 • 2年前
    Yves Laure Pimentel

    3. PASSIVE IMMUNODIFFUSION

    3. PASSIVE IMMUNODIFFUSION

    Yves Laure Pimentel · 17問 · 2年前

    3. PASSIVE IMMUNODIFFUSION

    3. PASSIVE IMMUNODIFFUSION

    17問 • 2年前
    Yves Laure Pimentel

    4. OUCHTERLONY

    4. OUCHTERLONY

    Yves Laure Pimentel · 15問 · 2年前

    4. OUCHTERLONY

    4. OUCHTERLONY

    15問 • 2年前
    Yves Laure Pimentel

    5. ELECTROPHORETIC TECHNIQUE

    5. ELECTROPHORETIC TECHNIQUE

    Yves Laure Pimentel · 9問 · 2年前

    5. ELECTROPHORETIC TECHNIQUE

    5. ELECTROPHORETIC TECHNIQUE

    9問 • 2年前
    Yves Laure Pimentel

    6. IMMUNOELECTROPHORESIS (DOUBLE DIFFUSION)

    6. IMMUNOELECTROPHORESIS (DOUBLE DIFFUSION)

    Yves Laure Pimentel · 11問 · 2年前

    6. IMMUNOELECTROPHORESIS (DOUBLE DIFFUSION)

    6. IMMUNOELECTROPHORESIS (DOUBLE DIFFUSION)

    11問 • 2年前
    Yves Laure Pimentel

    7. IMMUNOFIXATION ELECTROPHORESIS

    7. IMMUNOFIXATION ELECTROPHORESIS

    Yves Laure Pimentel · 29問 · 2年前

    7. IMMUNOFIXATION ELECTROPHORESIS

    7. IMMUNOFIXATION ELECTROPHORESIS

    29問 • 2年前
    Yves Laure Pimentel

    問題一覧

  • 1

    NK cells + IL-2

    LAK cells

  • 2

    Against cancer

    LAK cells

  • 3

    capacity of killing NK-resistant fresh human tumor cells in short-term assays

    LAK cells

  • 4

    (-) Markers on T/B cells

    NK/Null/3rd population lymphocyte

  • 5

    Kills virus and tumor cells

    NK/Null/3rd population lymphocyte

  • 6

    CD 16, CD 56

    NK/Null/3rd population lymphocyte

  • 7

    Major humoral immunity (natural)

    Complement

  • 8

    “ICED”: Initiation, Chemotaxis, Engulfment, Digestion

    Phagocytosis

  • 9

    Phagocytosis

    “ICED”: Initiation, Chemotaxis, Engulfment, Digestion

  • 10

    Primitive pattern recognition receptor

    Direct phagocytosis

  • 11

    Via opsonins

    Indirect phagocytosis

  • 12

    CR3 (3rd C’ component)

    Initiation

  • 13

    Laminin receptor

    Initiation

  • 14

    Leucyl-formyl-methionyl-phenylalanine receptor

    Initiation

  • 15

    (potent chemotaxin)

    C5a

  • 16

    C5a (potent chemotaxin)

    Chemotaxis

  • 17

    = test for chemotaxis

    Boyden Chamber assay

  • 18

    C3b (opsonin)

    Engulfment

  • 19

    From eosinophils and mast cells

    Histamine

  • 20

    Vasodilation

    Histamine

  • 21

    Lymphokine activating factor

    IL-1

  • 22

    Secreted by monocytes and macrophages

    IL-1

  • 23

    Mediates fever

    IL-1

  • 24

    INCREASED APR’s

    IL-1

  • 25

    Stabilize the wound area

    Fibroblasts

  • 26

    has been recognized as the prototype acute phase reactant

    CRP

  • 27

    INCREASED 20-1,000x

    CRP Serum amyloid A

  • 28

    Young cells

    Fibroblasts

  • 29

    Leukocyte IFN (Type 1

    IFN-a

  • 30

    Produced by viral-induced leukocyte culture

    IFN-a

  • 31

    Major producer: NK cell

    IFN-a

  • 32

    IFN-a Major producer:

    NK cell

  • 33

    WHAT TYPE? IFN-α

    Leukocyte IFN (Type 1)

  • 34

    WHAT TYPE? IFN-β

    Fibroepithelial IFN (Type 1)

  • 35

    Fibroepithelial IFN (Type 1)

    IFN-β

  • 36

    Produced by dsRNA fibroblast cells

    IFN-ß

  • 37

    WHAT TYPE? IFN-γ

    Immune interferon (Type 2)

  • 38

    Produced by immunologically-stimulated lymphocytes

    IFN-γ

  • 39

    is a cytokine that is critical for innate and adaptive immunity against viral, some bacterial and protozoan infections

    IFN-γ

  • 40

    TNF-α AKA

    Cachectin

  • 41

    Produced by macrophages

    TNF-α AKA Cachectin

  • 42

    TNF-β AKA

    Lymphotoxin

  • 43

    Produced by CD4+ and CD8+ lymphocytes

    TNF-β AKA Lymphotoxin

  • 44

    TNF-β AKA Lymphotoxin Produced by ?

    CD4+ and CD8+ lymphocytes

  • 45

    (3) Large capsule Cause meningitis

    H. influenzae N. meningitidis S. pneumoniae

  • 46

    (-) NADPH oxidase

    CGD

  • 47

    Test for CGD

    NBT dye test

  • 48

    Regulates body temperature (fever)

    Hypothalamus

  • 49

    increased γ-globulins (increased plasma cells)

    Chronic inflammation

  • 50

    Antigen in unrelated plants and animals but are closely linked that they cross react with one another

    Heterophile antigens

  • 51

    Order of activation (C’)

    C142356789

  • 52

    Serum protein Bactericidal and viricidal Needs C3 and Mg2+

    Properdin

  • 53

    Bactericidal and viricidal

    Properdin

  • 54

    Needs C3 and Mg2+

    Properdin

  • 55

    Released by platelets

    Betalysin

  • 56

    is an amino acid produced by platelets during coagulation and is directly antibacterial by causing lysis of many Gram positive bacteria by acting as a cationic detergent

    β-Lysine

  • 57

    Against Gram (+) except Streptococcus

    β-Lysine

  • 58

    β-Lysine Against Gram (+) except ?

    Streptococcus

  • 59

    Antibody production is done by the body

    Active immunity

  • 60

    Active immunity Advantage:

    Long term

  • 61

    Active immunity Disadvantage:

    slow response

  • 62

    Infection (Ag)

    Active natural

  • 63

    Vaccination (Ag)

    Active artificial

  • 64

    Vaccines: 1. Live =

    smallpox

  • 65

    Vaccines: 1. = smallpox

    Live

  • 66

    Vaccines: Attenuated =

    BCG-Bacillus Calmette Guérin (M. bovis)

  • 67

    Vaccines: Dead =

    cholera, typhoid

  • 68

    Vaccines: = cholera, typhoid

    Dead

  • 69

    Vaccines: = BCG (M. bovis)

    Attenuated

  • 70

    Vaccines: Toxoid =

    C. tetani

  • 71

    Vaccines: = C. tetani

    Toxoid

  • 72

    Vaccines: Modified virus =

    poliovirus

  • 73

    Vaccines: = poliovirus

    Modified virus

  • 74

    Antibody production is not done by the body

    Passive immunity

  • 75

    Passive immunity Advantage:

    Immediate

  • 76

    Passive immunity Disadvantage:

    short term

  • 77

    Transfer in vivo (Ab)

    Passive natural

  • 78

    Immune serum Ig’s administration (Ab) Ex. anti-rabies

    Passive artificial

  • 79

    German word: Swelling

    Quellung

  • 80

    Quellung also called the

    Neufeld reaction

  • 81

    gold standard method for pneumococcal capsular serotyping

    Quellung test

  • 82

    Highest eosinophil count

    T. spiralis

  • 83

    Maturation of T and B cells

    1’/ PRIMARY lymphoid organs

  • 84

    Proliferation and differentiation of T and B cells

    2’/ Secondary lymphoid organs

  • 85

    2’/ Secondary lymphoid organs

    Spleen Peyer’s patches Lymph nodes

  • 86

    generally regarded as a B-dependent area

    lymph node cortex

  • 87

    Lymph nodes Cortex =

    B cells

  • 88

    Lymph nodes Paracortex =

    T cells

  • 89

    T cells are found mainly in the

    Paracortex

  • 90

    % of total lymphocytes

    80%

  • 91

    Sheep RBC receptor, classical T-cell surface marker

    CD2

  • 92

    CD? (4) T lymphocytes

    CD2 CD3 CD4 CD8

  • 93

    part of T cell Ag-receptor complex

    CD3

  • 94

    MHC class II (Th)

    CD4

  • 95

    = MHC class I (Tc/Ts)

    CD8

  • 96

    the development in an individual of the immune system from fetal life though adulthood

    Ontogeny

  • 97

    Ontogeny of T cells (Thymus) Cortex =

    Immature (85% )

  • 98

    Ontogeny of T cells (Thymus) PART? = Immature (85% )

    Cortex

  • 99

    Ontogeny of T cells (Thymus) PART? = Mature (15%)

    Medulla

  • 100

    Ontogeny of T cells (Thymus) Medulla =

    Mature (15%)